AR053990A1 - Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion. - Google Patents

Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.

Info

Publication number
AR053990A1
AR053990A1 ARP050105253A ARP050105253A AR053990A1 AR 053990 A1 AR053990 A1 AR 053990A1 AR P050105253 A ARP050105253 A AR P050105253A AR P050105253 A ARP050105253 A AR P050105253A AR 053990 A1 AR053990 A1 AR 053990A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
pirazolpiridina
inhibitor
compact
factor
Prior art date
Application number
ARP050105253A
Other languages
English (en)
Spanish (es)
Inventor
Michael J Orwat
Mary F Malley
Roxana F Schlam
Steven R Fabian
Bing-Shiou Yang
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR053990A1 publication Critical patent/AR053990A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP050105253A 2004-12-15 2005-12-14 Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion. AR053990A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
AR053990A1 true AR053990A1 (es) 2007-05-30

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105253A AR053990A1 (es) 2004-12-15 2005-12-14 Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.

Country Status (15)

Country Link
US (2) US7371864B2 (2)
EP (1) EP1828187A2 (2)
JP (1) JP2008524228A (2)
KR (1) KR20070087606A (2)
AR (1) AR053990A1 (2)
AU (1) AU2005317158A1 (2)
BR (1) BRPI0519331A2 (2)
CA (1) CA2589886A1 (2)
IL (1) IL183825A0 (2)
MX (1) MX2007006919A (2)
NO (1) NO20072666L (2)
PE (1) PE20060739A1 (2)
RU (1) RU2007126770A (2)
TW (1) TW200634011A (2)
WO (1) WO2006065853A2 (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5588970B2 (ja) 2008-05-27 2014-09-10 ダコ・デンマーク・エー／エス ハイブリダイゼーション組成物及び方法
US9303287B2 (en) * 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US10662465B2 (en) 2011-09-30 2020-05-26 Agilent Technologies, Inc. Hybridization compositions and methods using formamide
US11118226B2 (en) 2011-10-21 2021-09-14 Agilent Technologies, Inc. Hybridization compositions and methods
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CN104744461A (zh) * 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor

Also Published As

Publication number Publication date
IL183825A0 (en) 2007-09-20
KR20070087606A (ko) 2007-08-28
AU2005317158A1 (en) 2006-06-22
BRPI0519331A2 (pt) 2009-01-20
US20080188517A1 (en) 2008-08-07
JP2008524228A (ja) 2008-07-10
WO2006065853A3 (en) 2006-08-24
US7371864B2 (en) 2008-05-13
MX2007006919A (es) 2007-06-26
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
PE20060739A1 (es) 2006-08-16
RU2007126770A (ru) 2009-01-27
EP1828187A2 (en) 2007-09-05
NO20072666L (no) 2007-09-07
WO2006065853A2 (en) 2006-06-22
CA2589886A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
CR9881A (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
JP2005526058A5 (2)
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
NO20071534L (no) Behandling av inflammatoriske forstyrrelser og smerte
DK1613335T3 (da) Blodkardannelse induceret af perivaskulære mesenchymale precursorceller
EP2078320A4 (en) MICRO-MACHINED ELECTROLYTIC SHEET, FUEL CELL DEVICES USING THE SAME, AND MICRO-MACHINING METHOD OF MANUFACTURING FUEL CELL DEVICES
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
EA200300348A1 (ru) Спирогетероциклические нитрилы, пригодные для применения в качестве обратимо действующих ингибиторов цистеиновых протеаз
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
ID30180A (id) Penggunaan dari turunan-turunan 4-h-1-benzopiran-4-on sebagai inhibitor dari proliferasi sel otot polos
PE20090742A1 (es) Formas solidas de (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)-pirimidin-4-il)fenil)propanoato de etilo y metodos para su uso
SE0302324D0 (sv) Novel compounds
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
EP1816170A4 (en) AZO COMPOUNDS AND POLYMERIZING FILMS OR PLATES CONTAINING THE SAME
AR053990A1 (es) Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.
SE0203304D0 (sv) Novel Coumpounds
EP1740183B8 (en) Novel use for pde5 inhibitors
UY31866A (es) Combinaciones farmacéuticas comprendiendo los compuestos 3-z[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilene]-6-metoxicarbonil-2-indolinona y el ácido n-[4-[2-(2-amino-4,7-dihidro-4-oxo-1h-pirrolo [2,3-d] pirimidin-5-il)etil]benzoil]-l-glutamico; sus sales farmacéuticamente aceptables y aplicaciones
IL174833A0 (en) Thioether-substituted benzamides as inhibitors of factor xa
MX2007011493A (es) Modalidades antiinflamatorias.
ATE412985T1 (de) Verbesserungen in der verwendung von brennstoff in elektrochemischen brennstoffzellen
SE0202461D0 (sv) Novel compounds
ECSP056038A (es) Procedimiento para la preparación de un polimorfo de maleato de rosiglitazona
CL2007002524A1 (es) Forma cristalina talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso para el tratamiento de una en

Legal Events

Date Code Title Description
FB Suspension of granting procedure